Artbio
Latest round
- Series B
Last raised
- Jul 2025
Total raised
- $245M
Investors
- 7
About Artbio
Founded in 2021 and headquartered in Cheshire, UK, Artbio Limited specializes in developing targeted radioligand therapies.ARTBIO specializes in the development of a new class of alpha radioligand therapies (ART) aimed at enhancing cancer treatment efficacy and safety. The company's core offerings focus on targeted radioligand therapies that leverage high-affinity and selective drug molecules to effectively eradicate tumors while minimizing damage to healthy tissues. ARTBIO's lead program, AB001, has advanced into first-in-human studies, with additional programs targeting multiple solid tumors also in various stages of development.ARTBIO's revenue is primarily generated through collaborations with healthcare providers and institutions that utilize their alpha radioligand therapies in cancer treatment. The company adopts a business-to-business (B2B) model, facilitating transactions directly with medical facilities and pharmaceutical partners. Revenue is derived from contracts related to clinical trials, product sales, and potential licensing agreements for their proprietary therapies, such as AB001. The company is focused on expanding its portfolio with new alpha radioligand therapies targeting various cancers and intends to enter new markets, particularly in Europe and North America, by 2026. Through strategic partnerships and advancements in clinical trials, ARTBIO aims to enhance its market presence in the oncology field.
Who invested in Artbio
7 investors across 3 rounds
See all investors in Artbio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Artbio
Who invested in Artbio?
Artbio has 7 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Artbio raised?
Artbio has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Artbio last raise money?
Artbio's most recent round on record is a Series B, in Jul 2025.
What does Artbio do?
Founded in 2021 and headquartered in Cheshire, UK, Artbio Limited specializes in developing targeted radioligand therapies.
Where is Artbio headquartered?
Artbio is headquartered in Cheshire, UK.
Which VCs invest in companies like Artbio?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Artbio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Artbio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.